Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hematologic malignancies. Its proprietary chRDNA genome-editing technology enables multiplex editing with high precision. Lead candidates include vispa-cel (anti-CD19, for r/r B-NHL) and CB-011 (anti-BCMA, for r/r multiple myeloma), both in phase 1 clinical trials. The company discontinued CB-012 (anti-CLL-1 for r/r AML) and reduced its workforce by 32% in April 2025.
expected 2026-11-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001619856-26-000008 | EDGAR | 107K words |
| 2025-03-10 | 2024-12-31 | 0001619856-25-000015 | EDGAR | 109K words |
| 2024-03-11 | 2023-12-31 | 0001619856-24-000013 | EDGAR | 109K words |
| 2023-03-09 | 2022-12-31 | 0001619856-23-000037 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0000950170-22-004233 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001619856-26-000055 | EDGAR | 17K words |
| 2025-11-12 | 2025-09-30 | 0001619856-25-000071 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0001619856-25-000061 | EDGAR | 22K words |
| 2025-05-08 | 2025-03-31 | 0001619856-25-000043 | EDGAR | 20K words |
| 2024-11-06 | 2024-09-30 | 0001619856-24-000081 | EDGAR | 22K words |
| 2024-08-06 | 2024-06-30 | 0001619856-24-000064 | EDGAR | 21K words |
| 2024-05-07 | 2024-03-31 | 0001619856-24-000038 | EDGAR | 19K words |
| 2023-11-07 | 2023-09-30 | 0001619856-23-000124 | EDGAR | 25K words |
| 2023-08-08 | 2023-06-30 | 0001619856-23-000107 | EDGAR | 24K words |
| 2023-05-09 | 2023-03-31 | 0001619856-23-000071 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001619856-22-000022 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016053 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001619856-26-000053 | EDGAR | 3K words |
| 2026-03-31 | 0001619856-26-000012 | EDGAR | 1K words |
| 2026-03-05 | 0001619856-26-000007 | EDGAR | 3K words |
| 2025-11-12 | 0001619856-25-000070 | EDGAR | 3K words |
| 2025-11-03 | 0001619856-25-000065 | EDGAR | 12K words |
| 2025-08-12 | 0001619856-25-000060 | EDGAR | 3K words |
| 2025-06-23 | 0001619856-25-000052 | EDGAR | 1K words |
| 2025-06-13 | 0001619856-25-000047 | EDGAR | 1K words |
| 2025-05-08 | 0001619856-25-000040 | EDGAR | 2K words |
| 2025-04-24 | 0001619856-25-000023 | EDGAR | 2K words |
104 total filings indexed. 77 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001619856 |
| Ticker | CRBU |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cariboubio.com |
| Listed | 2021-07-23 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CRBU (~200 tokens, structured JSON with cryptographic provenance)